Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) hit a new 52-week high during trading on Tuesday . The stock traded as high as C$0.10 and last traded at C$0.09, with a volume of 5000 shares. The stock had previously closed at C$0.09.
Hemostemix Trading Down 9.1 %
The firm has a market cap of C$8.71 million, a price-to-earnings ratio of -5.00 and a beta of 0.20. The stock’s 50 day moving average is C$0.09 and its 200 day moving average is C$0.06.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- What Are Dividend Challengers?
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Retail Stocks Investing, Explained
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- Investing in Construction Stocks
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
